• SPX
  • $5,917.11
  • 0 %
  • $0.13
  • DJI
  • $43,408.47
  • 0.32 %
  • $139.53
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,110.82
  • 0.32 %
  • $25.75
  • IXIC
  • $18,966.14
  • -0.11 %
  • -$21.33
NovoCure Limited (NVCR) Stock Price, News & Analysis

NovoCure Limited (NVCR) Stock Price, News & Analysis

Currency in USD Disclaimer

$16.85

$0.37

(2.25%)

Day's range
$16.22
Day's range
$17.35
50-day range
$14.17
Day's range
$21.82
  • Country: JE
  • ISIN: JE00BYSS4X48
52 wk range
$11.29
Day's range
$24.74


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.46
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (NVCR)
  • Company NovoCure Limited
  • Price $16.85
  • Changes Percentage (2.25%)
  • Change $0.37
  • Day Low $16.22
  • Day High $17.35
  • Year High $24.74

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $36.00
  • High Stock Price Target $200.00
  • Low Stock Price Target $14.50
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.81
  • Trailing P/E Ratio -11.88
  • Forward P/E Ratio -11.88
  • P/E Growth -11.88
  • Net Income $-207,043,000

Income Statement

Quarterly

Annual

Latest News of NVCR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

NovoCure Limited Frequently Asked Questions

  • What were the earnings of NVCR in the last quarter?

    In the last quarter NovoCure Limited earnings were on Wednesday, October, 30th. The NovoCure Limited maker reported -$0.28 EPS for the quarter, beating analysts' consensus estimates of -$0.34 by $0.06.

  • What is the NovoCure Limited stock price today?

    Today's price of NovoCure Limited is $16.85 — it has increased by +2.25% in the past 24 hours. Watch NovoCure Limited stock price performance more closely on the chart.

  • Does NovoCure Limited release reports?

    Yes, you can track NovoCure Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the NovoCure Limited stock forecast?

    Watch the NovoCure Limited chart and read a more detailed NovoCure Limited stock forecast to see what analysts suggest you do with its shares.

  • What is NovoCure Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by NovoCure Limited stock ticker.

  • How to buy NovoCure Limited stocks?

    Like other stocks, NVCR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is NovoCure Limited's EBITDA?

    NovoCure Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in NovoCure Limited’s financial statements.

  • What is the NovoCure Limited's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.4064943122, which equates to approximately -40.65%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in NovoCure Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including NovoCure Limited's financials relevant news, and technical analysis. NovoCure Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for NovoCure Limited stock currently indicates a “sell” signal. For more insights, review NovoCure Limited’s technical analysis.

  • A revenue figure for NovoCure Limited for its last quarter?

    NovoCure Limited published it's last quarterly revenues at $155.10 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.